- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03588975
Um estudo de MACI em pacientes de 10 a 17 anos com defeitos sintomáticos condrais ou osteocondrais do joelho (PEAK)
Um Estudo Clínico Prospectivo, Aberto, Randomizado, Simultâneo Ativo-Controlado, Longitudinal, Multicêntrico, Fase 3 da Segurança e Eficácia do MACI em Pacientes de 10 a 17 Anos com Defeitos Condrais ou Osteocondrais Sintomáticos do Joelho Devido a Osteocondrite Dissecante ou Trauma Agudo
The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a 2-year prospective, multicenter, randomized, open-label, parallel group clinical trial; a total of 45 participants, ages 10 to 17 years, will be randomized to receive a 1-time treatment with MACI or microfracture (2:1, 30 MACI:15 microfracture).
After meeting screening criteria at the initial visit, all participants will have a screening arthroscopy to further assess study eligibility. During the screening arthroscopy, participants will be further evaluated against entry criteria. Cartilage lesion size will be measured prior to any cartilage repair procedure and randomization. All participants who meet the eligibility criteria and are considered suitable for treatment in the study will have a cartilage biopsy taken prior to randomization to study treatment. Eligible participants will be randomized during the screening arthroscopy procedure to receive either MACI or microfracture treatment. Participants randomized to microfracture will undergo the procedure during the screening arthroscopy.
All biopsied tissue will be sent to the Vericel manufacturing facility in Massachusetts, where the sample will be processed to isolate the autologous chondrocytes. Cells from participants randomized to the MACI group will be used in the preparation of the MACI implant; cells from participants randomized to the microfracture group will be cryopreserved.
Participants randomized to treatment with MACI will return within 12 weeks of the screening arthroscopy to undergo the chondrocyte implantation procedure via arthrotomy. Participants are to follow a recommended postoperative rehabilitation program and compliance with the rehabilitation schedule will be monitored.
Participants will be followed post-study treatment for 2 years (104 Weeks).
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Vericel Clinical Affairs
- Número de telefone: 978-347-2876
- E-mail: clinicalhotline@vcel.com
Locais de estudo
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Recrutamento
- Stanford University School of Medicine
-
Contato:
- Amishi Jobanputra
- Número de telefone: 650-498-4180
- E-mail: amishij@stanford.edu
-
Investigador principal:
- Kevin Shea
-
Sacramento, California, Estados Unidos, 95817
- Recrutamento
- Shriners Hospital for Children Northern California
-
Investigador principal:
- Brian Haus
-
Contato:
- Kory Bettencourt
- Número de telefone: 916-453-5030,
- E-mail: kbettencourt@shrinenet.org
-
Sacramento, California, Estados Unidos, 95817
- Recrutamento
- University of California Davis Lawrence J. Ellison Ambulatory Care Center Orthopaedic Surgery
-
Investigador principal:
- Brian Haus
-
Contato:
- Julia Martin
- Número de telefone: 916-734-8175
- E-mail: jyhmartin@health.ucdavis.edu
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Recrutamento
- Ochsner Health System-Elmwood
-
Contato:
- Joseph Laurent
- Número de telefone: 504-842-0263
- E-mail: Joseph.laurent@ochsner.org
-
Investigador principal:
- Brian Godshaw
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21224
- Recrutamento
- Johns Hopkins Hospital
-
Contato:
- Rushyuan Jay Lee, MD
- Número de telefone: 443-997-2663
- E-mail: rlee74@jhmi.edu
-
Contato:
- Gabrielle Reichard
- Número de telefone: 410-502-3626
- E-mail: greicha1@jhmi.edu
-
Investigador principal:
- Rushyuan Jay Lee
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Recrutamento
- University of Michigan Medsport Orthopaedic Surgery
-
Contato:
- Christopher Ray
- Número de telefone: 734-615-0934
- E-mail: raychri@med.umich.edu
-
Investigador principal:
- Eileen Crawford
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Concluído
- Montefiore Medical Center/Albert Einstein College of Medicine
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44308
- Recrutamento
- Akron Children's Hospital
-
Contato:
- John Polousky, MD
- Número de telefone: 330-543-3500
- E-mail: JPolousky@akronchildrens.org
-
Investigador principal:
- John Polousky
-
Columbus, Ohio, Estados Unidos, 43202
- Recrutamento
- The Ohio State University Jameson Crane Sports Medicine Institute
-
Contato:
- Jenna DeFranco
- Número de telefone: 614-293-2761
- E-mail: jenna.defranco@osumc.edu
-
Investigador principal:
- Christopher Kaeding
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Penn Medicine University City
-
Contato:
- Dorothy Brill
- Número de telefone: 215-273-5062
- E-mail: dcbrill@upenn.edu
-
Investigador principal:
- James Carey
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- The Children's Hospital of Philadelphia - The Hub for Clinical Collaboration
-
Contato:
- Divya Talwar
- Número de telefone: 215-590-1527
- E-mail: talward@chop.edu
-
Investigador principal:
- Theodore Ganley
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- Recrutamento
- University Orthopedics, Inc.
-
Contato:
- Cyndi Chrostek
- Número de telefone: 401-318-0529
- E-mail: cchrostek@brownhealth.org
-
Investigador principal:
- Nicholas Lemme
-
-
Texas
-
Houston, Texas, Estados Unidos, 77094
- Concluído
- Texas' Children Hospital
-
Plano, Texas, Estados Unidos, 75024
- Concluído
- Children's Medical Center Plano
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53201
- Recrutamento
- Children's Hospital of Wisconsin
-
Contato:
- John Erickson, DO
- Número de telefone: 414-337-7325
- E-mail: JErickson2@childrenswi.org
-
Investigador principal:
- John Erickson
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Age 10 to 17 years at the time of planned randomization
-
Symptomatic cartilage or osteochondral defects
-
One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).
- Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.
- Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.
-
At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.
-
Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.
-
Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.
-
Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.
-
Written informed consent
Exclusion Criteria:
-
Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)
-
Previous investigational drug or device use within 3 months prior to Screening
-
Avascular necrosis of the target knee (other than potential OCD lesion to be treated)
-
Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate
-
ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion
-
Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)
-
Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint
-
Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)
-
Known history of septic arthritis in the index knee joint
-
Current malignancy or treatment for malignancy within the past 5 years
-
Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin
-
Females who are pregnant or lactating
-
Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:
- Any condition that has potential for negatively impacting intra or postoperative course
- Conditions that limit compliance with rehabilitation program
- Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function
- Any condition, psychiatric or otherwise, that would preclude informed consent/assent, consistent follow-up, or compliance with any aspect of the study
- Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: MACI
autologous cultured chondrocytes on porcine collagen membrane |
autologous cultured chondrocytes on porcine collagen membrane |
|
Outro: microfracture
surgical procedure |
Arthroscopic microfracture treatment |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants Who Achieve ≥ 10-point Improvement From Baseline in KOOS-Child Pain and Function (Sports and Recreational Activities) Subscale Scores
Prazo: Baseline and Week 104
|
A responder is defined as a participant with ≥ 10-point change (improvement) in both the KOOS-Child Pain and Function (Sports and Recreational activities) scores from Baseline scores. The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in KOOS-Child subscores
Prazo: Baseline and Week 104
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 104
|
|
Change from Baseline in KOOS-Child subscores
Prazo: Baseline and Week 52
|
The Knee and Osteoarthritis Outcome Score for Children (KOOS-Child) is a validated knee-specific instrument developed to assess the participant's opinion of their knee and associated problems. KOOS consists of 5 subscales: Pain, Function in sports and recreational activities, other Symptoms, Function in activities of daily living (ADL), and knee related Quality of life (QOL). |
Baseline and Week 52
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment Emergent Adverse Events
Prazo: Week 104
|
A treatment emergent untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. |
Week 104
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Jonathan Hopper, BSc (Hons), MB ChB, FRCSEd, Vericel Corporation
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 55-1702-1
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .